Page last updated: 2024-09-03

imatinib mesylate and Dyslipidemia

imatinib mesylate has been researched along with Dyslipidemia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cundy, T; Grey, A; Porter, D	1
Abruzzese, E; Aprile, L; Baratè, C; Bocchia, M; Bosi, A; Defina, M; Fontanelli, G; Galimberti, S; Gozzetti, A; Gozzini, A; Petrini, M; Puccetti, L; Santilli, F; Scappini, B; Sicuranza, A; Trawinska, MM	1

Other Studies

2 other study(ies) available for imatinib mesylate and Dyslipidemia

Article	Year
Hypertrophic osteoarthropathy with imatinib therapy. Internal medicine journal, 2015, Volume: 45, Issue:10 Topics: Alkaline Phosphatase; Antineoplastic Agents; Diabetes Mellitus, Type 2; Dyslipidemias; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Vitiligo	2015
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget, 2016, Nov-01, Volume: 7, Issue:44 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atherosclerosis; Cross-Sectional Studies; Cytokines; Dyslipidemias; Female; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Incidence; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oxidation-Reduction; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Thrombosis	2016

Article

Year

Hypertrophic osteoarthropathy with imatinib therapy.

Internal medicine journal, 2015, Volume: 45, Issue:10

Topics: Alkaline Phosphatase; Antineoplastic Agents; Diabetes Mellitus, Type 2; Dyslipidemias; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Vitiligo

2015

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.

Oncotarget, 2016, Nov-01, Volume: 7, Issue:44

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atherosclerosis; Cross-Sectional Studies; Cytokines; Dyslipidemias; Female; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Incidence; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oxidation-Reduction; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Thrombosis

2016